Prognostic value of plasma neuropeptide-Y in coronary care unit patients with and without acute myocardial infarction.
Plasma neuropeptide Y-like immunoreactivity (NPY-LI) is elevated in patients with acute myocardial ischaemia and congestive heart failure (CHF) owing to increased activity of the sympathetic nervous system. The prognostic value of plasma NPY-LI with regard to mortality was studied in 324 random patients admitted to a coronary care unit. The one-year mortality was 37% in 113 patients with acute myocardial infarction (AMI) and 18% in those without AMI. Several factors were tested by multiple logistical regression analysis to predict the one-year mortality. Plasma NPY-LI > 60 pmol.l-1, advanced age and previous CHF were independent prognostic factors for an increased risk of mortality in patients without AMI. The mortality rate after one year in non-AMI patients with plasma NPY-LI < or = 60 pmol.l-1 was 14% compared to 69% in those with plasma NPY-LI > 60 pmol.l-1. Increased heart rate was the only independent prognostic factor for increased mortality in AMI patients. Plasma NPY-LI on admission was an independent predictor of mortality in CCU patients without AMI and thus resembles plasma noradrenaline.
Ullman
B
B
Department of Cardiology, Söder Hospital, Stockholm, Sweden.
Hulting
J
J
Lundberg
J M
JM
D000368:Aged; D001145:Arrhythmias, Cardiac / Q000097:blood* / Q000401:mortality; D005260:Female; D006333:Heart Failure / Q000097:blood* / Q000401:mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood* / Q000401:mortality; D009478:Neuropeptide Y / Q000097:blood*; D011379:Prognosis; D012307:Risk Factors; D012680:Sensitivity and Specificity; D015996:Survival Rate
D009478:Neuropeptide Y